Citations 13
SAFETY AND EFFICACY OF THE PD‐L1 INHIBITOR DURVALUMAB WITH R‐CHOP OR R2‐CHOP IN SUBJECTS WITH PREVIOUSLY UNTREATED, HIGH‐RISK DLBCL
Nowakowski, Grzegorz S. , Willenbacher, Wolfgang , Greil, Richard , Larsen, Thomas Stauffer , Manges, Robert, Trümper, Lorenz, Everaus, Hele, Kalakonda, Nagesh , Knoble, Jeanna, Jørgensen, Judit , Rubio, Neus Domper, Casadebaig, Marie‐Laure, Manzke, Oliver, Cunningham, David , Patel, Krish , Jäger, Ulrich , Haïoun, Corinne , Brown, Peter de Nully , Cunningham, David , Muñoz, Javier
Hematological Oncology | June 12, 2019 | Volume: 37 | Issue: S2 | Pages: 132-134
OUTCOMES AFTER EARLY TRANSFORMATION (tPOD24) VS. EARLY FOLLICULAR LYMPHOMA PROGRESSION (fPOD24) IN FOLLICULAR LYMPHOMA TREATED WITH FRONTLINE IMMUNOCHEMOTHERAPY
Jakopsen, L.H., Nowakowski, G. S., Ansell, Steven M., Thompson, Chester Andrew , Jørgensen, Judit , Frederiksen, Henrik , Novak, Anne J. , Frederiksen, Henrik , Maurer, Matthew J. , Habermann, Thomas M. , Brown, Peter de Nully , Syrbu, Sergei , Feldman, Andrew L. , Rimsza, Lisa M. , Cerhan, James R. , El‐Galaly, Tarec Christoffer , Link, Brian K.
Hematological Oncology | June 12, 2019 | Volume: 37 | Issue: S2 | Pages: 231-232
Up-front rituximab maintenance improves outcome in patients with follicular lymphoma: a collaborative Nordic study
Clausen, Michael Roost , Plesner, Torben , Pasanen, Annika , Kuismanen, T., Bentzen, Hans, Jørgensen, Judit , Sillesen, Ida Blok, Himmelstrup, Bodil , Rønnov‐Jessen, Dorthe, Jensen, Kiersten, Pettinger, Adam, Ludvigsen, Maja , Leppä, Sirpa , d’Amore, Francesco, Joergensen, Judit Mészáros , Madsen, Charlotte Bernhard , Clausen, Michael Roost
Blood Advances | July 5, 2018 | Volume: 2 | Issue: 13 | Pages: 1562-1571
10.1182/bloodadvances.2018017673
Key PointsPatients who received R-chemo followed by MR had an improved 5-year PFS and OS independent of prognostic factors. A reduction of the risk of HT was observed among the MR patients of the training, but not of the validation, cohort.